350 related articles for article (PubMed ID: 32300059)
1. Myeloid-Derived Suppressor Cell Subsets Drive Glioblastoma Growth in a Sex-Specific Manner.
Bayik D; Zhou Y; Park C; Hong C; Vail D; Silver DJ; Lauko A; Roversi G; Watson DC; Lo A; Alban TJ; McGraw M; Sorensen M; Grabowski MM; Otvos B; Vogelbaum MA; Horbinski C; Kristensen BW; Khalil AM; Hwang TH; Ahluwalia MS; Cheng F; Lathia JD
Cancer Discov; 2020 Aug; 10(8):1210-1225. PubMed ID: 32300059
[TBL] [Abstract][Full Text] [Related]
2. Distinct Cell Adhesion Signature Defines Glioblastoma Myeloid-Derived Suppressor Cell Subsets.
Bayik D; Bartels CF; Lovrenert K; Watson DC; Zhang D; Kay K; Lee J; Lauko A; Johnson S; Lo A; Silver DJ; McGraw M; Grabowski M; Mohammadi AM; Veglia F; Fan Y; Vogelbaum MA; Scacheri P; Lathia JD
Cancer Res; 2022 Nov; 82(22):4274-4287. PubMed ID: 36126163
[TBL] [Abstract][Full Text] [Related]
3. Explicating the Pivotal Pathogenic, Diagnostic, and Therapeutic Biomarker Potentials of Myeloid-Derived Suppressor Cells in Glioblastoma.
Richard SA
Dis Markers; 2020; 2020():8844313. PubMed ID: 33204365
[TBL] [Abstract][Full Text] [Related]
4. Glioblastoma Myeloid-Derived Suppressor Cell Subsets Express Differential Macrophage Migration Inhibitory Factor Receptor Profiles That Can Be Targeted to Reduce Immune Suppression.
Alban TJ; Bayik D; Otvos B; Rabljenovic A; Leng L; Jia-Shiun L; Roversi G; Lauko A; Momin AA; Mohammadi AM; Peereboom DM; Ahluwalia MS; Matsuda K; Yun K; Bucala R; Vogelbaum MA; Lathia JD
Front Immunol; 2020; 11():1191. PubMed ID: 32625208
[TBL] [Abstract][Full Text] [Related]
5. Cancer Stem Cell-Secreted Macrophage Migration Inhibitory Factor Stimulates Myeloid Derived Suppressor Cell Function and Facilitates Glioblastoma Immune Evasion.
Otvos B; Silver DJ; Mulkearns-Hubert EE; Alvarado AG; Turaga SM; Sorensen MD; Rayman P; Flavahan WA; Hale JS; Stoltz K; Sinyuk M; Wu Q; Jarrar A; Kim SH; Fox PL; Nakano I; Rich JN; Ransohoff RM; Finke J; Kristensen BW; Vogelbaum MA; Lathia JD
Stem Cells; 2016 Aug; 34(8):2026-39. PubMed ID: 27145382
[TBL] [Abstract][Full Text] [Related]
6. Myeloid-Derived Suppressor Cell Subset Accumulation in Renal Cell Carcinoma Parenchyma Is Associated with Intratumoral Expression of IL1β, IL8, CXCL5, and Mip-1α.
Najjar YG; Rayman P; Jia X; Pavicic PG; Rini BI; Tannenbaum C; Ko J; Haywood S; Cohen P; Hamilton T; Diaz-Montero CM; Finke J
Clin Cancer Res; 2017 May; 23(9):2346-2355. PubMed ID: 27799249
[No Abstract] [Full Text] [Related]
7. Blocking IL1 Beta Promotes Tumor Regression and Remodeling of the Myeloid Compartment in a Renal Cell Carcinoma Model: Multidimensional Analyses.
Aggen DH; Ager CR; Obradovic AZ; Chowdhury N; Ghasemzadeh A; Mao W; Chaimowitz MG; Lopez-Bujanda ZA; Spina CS; Hawley JE; Dallos MC; Zhang C; Wang V; Li H; Guo XV; Drake CG
Clin Cancer Res; 2021 Jan; 27(2):608-621. PubMed ID: 33148676
[TBL] [Abstract][Full Text] [Related]
8. Global immune fingerprinting in glioblastoma patient peripheral blood reveals immune-suppression signatures associated with prognosis.
Alban TJ; Alvarado AG; Sorensen MD; Bayik D; Volovetz J; Serbinowski E; Mulkearns-Hubert EE; Sinyuk M; Hale JS; Onzi GR; McGraw M; Huang P; Grabowski MM; Wathen CA; Ahluwalia MS; Radivoyevitch T; Kornblum HI; Kristensen BW; Vogelbaum MA; Lathia JD
JCI Insight; 2018 Nov; 3(21):. PubMed ID: 30385717
[TBL] [Abstract][Full Text] [Related]
9. Monocytic and granulocytic myeloid derived suppressor cells differentially regulate spatiotemporal tumour plasticity during metastatic cascade.
Ouzounova M; Lee E; Piranlioglu R; El Andaloussi A; Kolhe R; Demirci MF; Marasco D; Asm I; Chadli A; Hassan KA; Thangaraju M; Zhou G; Arbab AS; Cowell JK; Korkaya H
Nat Commun; 2017 Apr; 8():14979. PubMed ID: 28382931
[TBL] [Abstract][Full Text] [Related]
10. CD4+ T effector memory cell dysfunction is associated with the accumulation of granulocytic myeloid-derived suppressor cells in glioblastoma patients.
Dubinski D; Wölfer J; Hasselblatt M; Schneider-Hohendorf T; Bogdahn U; Stummer W; Wiendl H; Grauer OM
Neuro Oncol; 2016 Jun; 18(6):807-18. PubMed ID: 26578623
[TBL] [Abstract][Full Text] [Related]
11. Granulocytic and Monocytic Myeloid-Derived Suppressor Cells are Functionally and Prognostically Different in Patients with Chronic Myeloid Leukemia.
Ahn A; Park CJ; Kim MS; Cho YU; Jang S; Bae MH; Lee JH; Lee JH; Koh KN; Im HJ
Ann Lab Med; 2021 Sep; 41(5):479-484. PubMed ID: 33824236
[TBL] [Abstract][Full Text] [Related]
12. Myeloid-Derived Suppressive Cells Promote B cell-Mediated Immunosuppression via Transfer of PD-L1 in Glioblastoma.
Lee-Chang C; Rashidi A; Miska J; Zhang P; Pituch KC; Hou D; Xiao T; Fischietti M; Kang SJ; Appin CL; Horbinski C; Platanias LC; Lopez-Rosas A; Han Y; Balyasnikova IV; Lesniak MS
Cancer Immunol Res; 2019 Dec; 7(12):1928-1943. PubMed ID: 31530559
[TBL] [Abstract][Full Text] [Related]
13. Genetic driver mutations introduced in identical cell-of-origin in murine glioblastoma reveal distinct immune landscapes but similar response to checkpoint blockade.
Chen Z; Herting CJ; Ross JL; Gabanic B; Puigdelloses Vallcorba M; Szulzewsky F; Wojciechowicz ML; Cimino PJ; Ezhilarasan R; Sulman EP; Ying M; Ma'ayan A; Read RD; Hambardzumyan D
Glia; 2020 Oct; 68(10):2148-2166. PubMed ID: 32639068
[TBL] [Abstract][Full Text] [Related]
14. Elevated levels of polymorphonuclear myeloid-derived suppressor cells in patients with glioblastoma highly express S100A8/9 and arginase and suppress T cell function.
Gielen PR; Schulte BM; Kers-Rebel ED; Verrijp K; Bossman SA; Ter Laan M; Wesseling P; Adema GJ
Neuro Oncol; 2016 Sep; 18(9):1253-64. PubMed ID: 27006175
[TBL] [Abstract][Full Text] [Related]
15. Immune consequences of penfluridol treatment associated with inhibition of glioblastoma tumor growth.
Ranjan A; Wright S; Srivastava SK
Oncotarget; 2017 Jul; 8(29):47632-47641. PubMed ID: 28512255
[TBL] [Abstract][Full Text] [Related]
16. Preclinical ImmunoPET Imaging of Glioblastoma-Infiltrating Myeloid Cells Using Zirconium-89 Labeled Anti-CD11b Antibody.
Nigam S; McCarl L; Kumar R; Edinger RS; Kurland BF; Anderson CJ; Panigrahy A; Kohanbash G; Edwards WB
Mol Imaging Biol; 2020 Jun; 22(3):685-694. PubMed ID: 31529407
[TBL] [Abstract][Full Text] [Related]
17. FGL2 as a Multimodality Regulator of Tumor-Mediated Immune Suppression and Therapeutic Target in Gliomas.
Yan J; Kong LY; Hu J; Gabrusiewicz K; Dibra D; Xia X; Heimberger AB; Li S
J Natl Cancer Inst; 2015 Aug; 107(8):. PubMed ID: 25971300
[TBL] [Abstract][Full Text] [Related]
18. Canonical NFκB signaling in myeloid cells is required for the glioblastoma growth.
Achyut BR; Angara K; Jain M; Borin TF; Rashid MH; Iskander ASM; Ara R; Kolhe R; Howard S; Venugopal N; Rodriguez PC; Bradford JW; Arbab AS
Sci Rep; 2017 Oct; 7(1):13754. PubMed ID: 29062041
[TBL] [Abstract][Full Text] [Related]
19. Modulation of temozolomide dose differentially affects T-cell response to immune checkpoint inhibition.
Karachi A; Yang C; Dastmalchi F; Sayour EJ; Huang J; Azari H; Long Y; Flores C; Mitchell DA; Rahman M
Neuro Oncol; 2019 Jun; 21(6):730-741. PubMed ID: 30668768
[TBL] [Abstract][Full Text] [Related]
20. Tumor Vessel Normalization, Immunostimulatory Reprogramming, and Improved Survival in Glioblastoma with Combined Inhibition of PD-1, Angiopoietin-2, and VEGF.
Di Tacchio M; Macas J; Weissenberger J; Sommer K; Bähr O; Steinbach JP; Senft C; Seifert V; Glas M; Herrlinger U; Krex D; Meinhardt M; Weyerbrock A; Timmer M; Goldbrunner R; Deckert M; Scheel AH; Büttner R; Grauer OM; Schittenhelm J; Tabatabai G; Harter PN; Günther S; Devraj K; Plate KH; Reiss Y
Cancer Immunol Res; 2019 Dec; 7(12):1910-1927. PubMed ID: 31597643
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
